$25.57
0[0.00%]
Last update: 4:20PM Get Real Time Here
Protagonist Therapeutics
(NASDAQ:PTGX)Protagonist Therapeutics Stock (NASDAQ:PTGX), Analyst Ratings, Price Targets, Predictions
Protagonist Therapeutics Inc has a consensus price target of $40.27, established from looking at the 36 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., JMP Securities, and JP Morgan on March 11, 2024, March 11, 2024, and February 28, 2024. With an average price target of $39 between HC Wainwright & Co., JMP Securities, and JP Morgan, there's an implied 52.52% upside for Protagonist Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
JMP Securities
JP Morgan
Capital One
Piper Sandler
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Protagonist Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/11/2024 | PTGX | Buy Now | Protagonist Therapeutics | $25.57 | 48.61% | HC Wainwright & Co. | Douglas Tsao | $38 → $38 | Maintains | Buy | Get Alert |
| 03/11/2024 | PTGX | Buy Now | Protagonist Therapeutics | $25.57 | 64.25% | JMP Securities | Jonathan Wolleben | → $42 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/28/2024 | PTGX | Buy Now | Protagonist Therapeutics | $25.57 | 44.7% | JP Morgan | Brian Cheng | $34 → $37 | Maintains | Overweight | Get Alert |
| 02/28/2024 | PTGX | Buy Now | Protagonist Therapeutics | $25.57 | 48.61% | HC Wainwright & Co. | Douglas Tsao | → $38 | Reiterates | Buy → Buy | Get Alert |
| 11/03/2023 | PTGX | Buy Now | Protagonist Therapeutics | $25.57 | 44.7% | JMP Securities | Jonathan Wolleben | $35 → $37 | Maintains | Market Outperform | Get Alert |
| 10/30/2023 | PTGX | Buy Now | Protagonist Therapeutics | $25.57 | — | Capital One | Tim Chiang | — | Initiates | → Overweight | Get Alert |
| 10/10/2023 | PTGX | Buy Now | Protagonist Therapeutics | $25.57 | 48.61% | HC Wainwright & Co. | Douglas Tsao | → $38 | Reiterates | Buy → Buy | Get Alert |
| 09/25/2023 | PTGX | Buy Now | Protagonist Therapeutics | $25.57 | 32.97% | JP Morgan | Brian Cheng | $36 → $34 | Maintains | Overweight | Get Alert |
| 08/04/2023 | PTGX | Buy Now | Protagonist Therapeutics | $25.57 | 48.61% | HC Wainwright & Co. | Douglas Tsao | → $38 | Reiterates | Buy → Buy | Get Alert |
| 07/10/2023 | PTGX | Buy Now | Protagonist Therapeutics | $25.57 | 48.61% | HC Wainwright & Co. | Douglas Tsao | → $38 | Reiterates | Buy → Buy | Get Alert |
| 07/06/2023 | PTGX | Buy Now | Protagonist Therapeutics | $25.57 | 36.88% | JMP Securities | Jonathan Wolleben | $28 → $35 | Maintains | Market Outperform | Get Alert |
| 07/03/2023 | PTGX | Buy Now | Protagonist Therapeutics | $25.57 | 36.88% | Piper Sandler | Yasmeen Rahimi | → $35 | Reiterates | Overweight → Overweight | Get Alert |
| 07/03/2023 | PTGX | Buy Now | Protagonist Therapeutics | $25.57 | 60.34% | BTIG | Julian Harrison | → $41 | Reiterates | → Buy | Get Alert |
| 06/12/2023 | PTGX | Buy Now | Protagonist Therapeutics | $25.57 | 48.61% | HC Wainwright & Co. | Douglas Tsao | → $38 | Reiterates | Buy → Buy | Get Alert |
| 04/27/2023 | PTGX | Buy Now | Protagonist Therapeutics | $25.57 | 48.61% | HC Wainwright & Co. | Douglas Tsao | → $38 | Reiterates | → Buy | Get Alert |
| 03/16/2023 | PTGX | Buy Now | Protagonist Therapeutics | $25.57 | 9.5% | JMP Securities | Jonathan Wolleben | $31 → $28 | Maintains | Market Outperform | Get Alert |
| 03/16/2023 | PTGX | Buy Now | Protagonist Therapeutics | $25.57 | 48.61% | HC Wainwright & Co. | Douglas Tsao | $33 → $38 | Maintains | Buy | Get Alert |
| 03/08/2023 | PTGX | Buy Now | Protagonist Therapeutics | $25.57 | 21.24% | JMP Securities | Jonathan Wolleben | $21 → $31 | Maintains | Market Outperform | Get Alert |
| 11/10/2022 | PTGX | Buy Now | Protagonist Therapeutics | $25.57 | 29.06% | HC Wainwright & Co. | Douglas Tsao | $50 → $33 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Protagonist Therapeutics (PTGX)?
The latest price target for Protagonist Therapeutics (NASDAQ: PTGX) was reported by HC Wainwright & Co. on March 11, 2024. The analyst firm set a price target for $38.00 expecting PTGX to rise to within 12 months (a possible 48.61% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Protagonist Therapeutics (PTGX)?
The latest analyst rating for Protagonist Therapeutics (NASDAQ: PTGX) was provided by HC Wainwright & Co., and Protagonist Therapeutics maintained their buy rating.
When was the last upgrade for Protagonist Therapeutics (PTGX)?
The last upgrade for Protagonist Therapeutics Inc happened on October 12, 2021 when JP Morgan raised their price target to $55. JP Morgan previously had a neutral for Protagonist Therapeutics Inc.
When was the last downgrade for Protagonist Therapeutics (PTGX)?
The last downgrade for Protagonist Therapeutics Inc happened on September 20, 2021 when JP Morgan changed their price target from N/A to $49 for Protagonist Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Protagonist Therapeutics (PTGX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Protagonist Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Protagonist Therapeutics was filed on March 11, 2024 so you should expect the next rating to be made available sometime around March 11, 2025.
Is the Analyst Rating Protagonist Therapeutics (PTGX) correct?
While ratings are subjective and will change, the latest Protagonist Therapeutics (PTGX) rating was a maintained with a price target of $38.00 to $38.00. The current price Protagonist Therapeutics (PTGX) is trading at is $25.57, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.